Munch-a-Biotech Today Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote ()	1/25/1999 10:12:00 PM
From: scaram(o)uche	Read Replies (2) of 3158

Doesn't fit the criteria that I'd usually apply, but.... I started trying to think of what companies might benefit from Merck's setback in depression. I think a good answer is SNAP. Together with Lilly, they have three molecules in development (do your own homework and check that, as it's only from some notes that I have), one of which is in human testing. Merck also has a relatively advanced program with SNAP in BPH. So, I thought that perhaps, given that they appear to be one molecule away from commanding hefty premiums for whatever they come up with (that is, the business plan is maturing on the breadth of the three clinical programs, including Lilly for migraine), that they might be a decent candidate as a takeover? Lots of partners, an independent, quiet company.... maybe when hell freezes over? Any thoughts?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next